Hepatocellular Carcinoma Clinical Trials in Kaohsiung City

8 recruitingKaohsiung City, Taiwan

Showing 18 of 8 trials

Recruiting
Phase 2

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Biliary Tract CancerHepatocellular Carcinoma
AstraZeneca294 enrolled60 locationsNCT05775159
Recruiting
Phase 3

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Hepatocellular Carcinoma
AstraZeneca1,220 enrolled204 locationsNCT06921785
Recruiting
Phase 2

CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma

Hepatocellular CarcinomaAdvanced Cancer
TaiRx, Inc.95 enrolled5 locationsNCT05257590
Recruiting
Phase 3

Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma

Hepatocellular CarcinomaAdvanced Hepatocellular Carcinoma
Polaris Group300 enrolled11 locationsNCT05317819
Recruiting
Phase 2

Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients

Locally Advanced Hepatocellular Carcinoma
National Cancer Centre, Singapore100 enrolled14 locationsNCT05377034
Recruiting
Phase 2

Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma

Hepatocellular Carcinoma
Lukas Biomedical Inc.95 enrolled13 locationsNCT05304481
Recruiting
Phase 1Phase 2

T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma
T-ACE Medical Co., Ltd90 enrolled4 locationsNCT05435014
Recruiting
Phase 4

Impact of Propofol-Based Total Intravenous Anesthesia Versus Anesthesia With Sevoflurane on Long-term Outcomes With Patients Undergoing Elective Excision of Primary Liver Tumors

Hepatocellular Carcinoma
Kaohsiung Medical University Chung-Ho Memorial Hospital500 enrolled1 locationNCT05331911